Biogen Latvia, a US-based company and one of the world's largest biotechnology companies for the development and commercialization of therapies specializing in neurological disease research, has joined the Chamber as a Corporate Contributing member. We warmly welcome them to AmCham!

Biogen was founded in 1978 and is one of the largest biotech companies, employing more than 7400 employees worldwide. The company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Biogen's turnover in 2019 was 14.4 billion US dollars.

In the Chamber it will be represented by Mikko Fernström, General Manager of Biogen Latvia.

Mikko Fernström, General Manager of Biogen Latvia about joining the Chamber: "We are very pleased to be part of AmCham Latvia community and are looking forward to drive innovation forward in Latvia".